This company listing is no longer active
KARO Stock Overview
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Karo Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr60.70 |
| 52 Week High | kr62.40 |
| 52 Week Low | kr49.25 |
| Beta | 0.10 |
| 1 Month Change | 0.50% |
| 3 Month Change | 1.17% |
| 1 Year Change | 4.84% |
| 3 Year Change | 56.85% |
| 5 Year Change | 57.66% |
| Change since IPO | -97.64% |
Recent News & Updates
Recent updates
Karo Pharma (STO:KARO) Has No Shortage Of Debt
Oct 14
Is Karo Pharma (STO:KARO) A Risky Investment?
Jul 10Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt
Mar 23Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality
Feb 24Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?
Feb 22Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?
Feb 01
Shareholder Returns
| KARO | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 0.5% | -1.8% | 0.7% |
| 1Y | 4.8% | -13.2% | -5.6% |
Return vs Industry: KARO exceeded the Swedish Pharmaceuticals industry which returned -23.2% over the past year.
Return vs Market: KARO exceeded the Swedish Market which returned -24.8% over the past year.
Price Volatility
| KARO volatility | |
|---|---|
| KARO Average Weekly Movement | 0.4% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 4.1% |
Stable Share Price: KARO is less volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 0% a week.
Volatility Over Time: KARO's weekly volatility (0%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 225 | Christoffer Lorenzen | https://www.karopharma.com |
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands.
Karo Pharma AB (publ) Fundamentals Summary
| KARO fundamental statistics | |
|---|---|
| Market Cap | kr16.59b |
| Earnings (TTM) | -kr189.85m |
| Revenue (TTM) | kr3.47b |
4.8x
P/S Ratio-87.4x
P/E RatioIs KARO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KARO income statement (TTM) | |
|---|---|
| Revenue | kr3.47b |
| Cost of Revenue | kr1.50b |
| Gross Profit | kr1.96b |
| Other Expenses | kr2.15b |
| Earnings | -kr189.85m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 56.67% |
| Net Profit Margin | -5.48% |
| Debt/Equity Ratio | 104.8% |
How did KARO perform over the long term?
See historical performance and comparison